Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 8 January 2009, Vol. 113, No. 2, pp. 328-337.
Prepublished online as a Blood First Edition Paper on October 21, 2008; DOI 10.1182/blood-2008-04-153882.


This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Methods and Figures
Right arrow All Versions of this Article:
blood-2008-04-153882v1
113/2/328    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bestebroer, J.
Right arrow Articles by de Haas, C. J.C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bestebroer, J.
Right arrow Articles by de Haas, C. J.C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted April 24, 2008
Accepted October 3, 2008

Staphylococcal SSL5 inhibits leukocyte activation by chemokines and anaphylatoxins

Jovanka Bestebroer*, Kok P.M. van Kessel, Hafida Azouagh, Annemiek M. Walenkamp, Ingrid G.J. Boer, Roland A. Romijn, Jos A.G. van Strijp, and Carla J.C. de Haas

Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands
Department of Oncology, University Medical Center Groningen, Groningen, Netherlands
U-Protein Express BV, Utrecht, Netherlands

* Corresponding author; email: j.bestebroer{at}umcutrecht.nl.

Staphylococcus aureus secretes several virulence factors modulating immune responses. Staphylococcal superantigen-like (SSL) proteins are a family of 14 exotoxins with homology to superantigens, but with generally unknown function. Recently, we demonstrated that SSL5 binds to P-selectin glycoprotein ligand 1 dependently of sialyl Lewis X and inhibits P-selectin-dependent neutrophil rolling. Here, we show that SSL5 potently and specifically inhibits leukocyte activation by anaphylatoxins and all classes of chemokines. SSL5 inhibited calcium mobilization, actin polymerization, and chemotaxis induced by chemokines and anaphylatoxins but not by other chemoattractants. Antibody competition experiments showed that SSL5 targets several chemokine and anaphylatoxin receptors. Additionally, transfection studies demonstrated that SSL5 binds glycosylated N-termini of all G protein-coupled receptors (GPCR) but only inhibits stimuli of protein nature that require the receptor N-terminus for activation. Furthermore, SSL5 increased binding of chemokines to cells independent of chemokine receptors through their common glycosaminoglycan-binding site. Importance of glycans was demonstrated for both GPCR and chemokine binding. Thus, SSL5 is an important immunomodulatory protein of S. aureus that targets several crucial, initial stages of leukocyte extravasation. It is therefore a potential new anti-inflammatory compound for diseases associated with chemoattractants and their receptors and disorders characterized by excessive recruitment of leukocytes.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020